Phase I Safety, Pharmacokinetics, and Clinical Activity Study of Lapatinib (GW572016), a Reversible Dual Inhibitor of Epidermal Growth Factor Receptor Tyrosine Kinases, in Heavily Pretreated Patients With Metastatic Carcinomas

Howard Burris,Herbert Hurwitz,E. Claire Dees,Afshin Dowlati,Kimberly L. Blackwell,Bert H. ONeil,Paul K. Marcom,Matthew Ellis,Beth Overmoyer,Suzanne F. Jones,Jennifer L. Harris,Deborah A. Smith,Kevin M. Koch,Andrew G. Stead,Steve Mangum,Neil L. Spector

Phase I Safety, Pharmacokinetics, and Clinical Activity Study of Lapatinib (GW572016), a Reversible Dual Inhibitor of Epidermal Growth Factor Receptor Tyrosine Kinases, in Heavily Pretreated Patients With Metastatic Carcinomas

2005

Howard Burris
Herbert Hurwitz
E. Claire Dees
Afshin Dowlati
Kimberly L. Blackwell
Bert H. ONeil
Paul K. Marcom
Matthew Ellis
Beth Overmoyer
Suzanne F. Jones
Jennifer L. Harris
Deborah A. Smith
Kevin M. Koch
Andrew G. Stead
Steve Mangum
Neil L. Spector

Purpose This study (EGF10004) assessed the safety/tolerability, pharmacokinetics, and clinical activity of daily oral dosing with lapatinib (GW572016) in patients with ErbB1-expressing and/or ErbB2-overexpressing advanced-stage refractory solid tumors.

Keywords:

Cancer research
Tyrosine kinase
Cancer
Epidermal growth factor receptor
Pathology
Metastasis
Lapatinib
Internal medicine
Pharmacokinetics
Endocrinology
Medicine
Tolerability
Growth factor receptor

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

557

Citations